Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business

ALACHUA, Fla.–(BUSINESS WIRE)–Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that industry veteran Timothy Cooke, Ph.D., has joined the Company as Senior Vice President of Commercial Business.

“Tim brings to Ology Bioservices more than 25 years of experience in the development of vaccines and immunotherapeutics at a number of emerging biotechnology and multinational pharmaceutical companies,” stated Peter H. Khoury, Ph.D., MBA, President and Chief Executive Officer of Ology Bioservices. “Having led several of these companies and having successfully built a global commercial vaccine organization, Tim’s expertise and relationships make him a perfect fit. We are delighted to welcome him to the company as we continue to expand our CDMO business and further develop our acquired vaccine assets.”

“Ology Bioservices is an emerging biologics CDMO that enables its clients to protect and improve human health through the application of innovative scientific approaches,” noted Dr. Cooke. “I am excited to become part of the Ology Bioservices team and look forward to leveraging my experience to build the business, further solidify our reputation and, most importantly, to assist our clients in the development of life-saving products.”

Since 2009, Dr. Cooke has served as the Chief Executive Officer of privately-held NovaDigm Therapeutics, a company focused on the development of vaccines and immunotherapeutics for the prevention or treatment of infections and bacterial pathogens. From 2004 to 2008, Dr. Cooke was Chief Operating Officer of AVANT Immunotherapeutics, where he led the product and commercial development functions for the company’s vaccine and biologic therapeutic pipeline. Earlier, from 2000 to 2004, Dr. Cooke was Chief Executive Officer of Mojave Therapeutics, and before that, was a founding member of Merck Vaccines, where he played a key role in building the company’s global sales and marketing organization.

Dr. Cooke has been active in global and national vaccine policy and was appointed Biotechnology Industry Representative Member, National Vaccine Advisory Committee of the U.S. Department of Health and Human Services for the 2015-2019 term. He earned both his Ph.D. in bio-organic chemistry and MBA from Columbia University, and holds a BS in chemistry from St. Joseph’s University.

About Ology Bioservices

Ology Bioservices is a full-service Contract Development Manufacturing Organization (CDMO) serving both government and commercial clients, specializing in biologic drug substance manufacturing, from early stage through commercial product. The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art, Department of Defense Advanced Development and Manufacturing Facility in Florida. The company’s infrastructure provides unique services to its clients, including full regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as cGMP manufacturing up to Biosafety Level 3 (BSL3). Ology Bioservices has 20 years of experience developing and manufacturing drugs and biologics for the U.S. Government, with over $500M in government contracts awarded over that time. The team at Ology Bioservices has decades of experience manufacturing, developing and licensing vaccines and protein/antibody therapeutics.


At Ology Bioservices, Inc.
Leslie Molony, Ph.D., 386-462-9663
Executive Director, Business Development
[email protected]
At Rx Communications Group, LLC
Melody A. Carey, 917-322-2571
President and Chief Executive Officer
[email protected]